Holen Sie sich die Stockscreener-App
0.6915
4.87%
0.0288
Schlusskurs vom Vortag:
$0.6627
Offen:
$0.662
24-Stunden-Volumen:
710.37K
Relative Volume:
0.51
Marktkapitalisierung:
$83.55M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-93.61M
KGV:
-0.3277
EPS:
-2.11
Netto-Cashflow:
$-71.16M
1W Leistung:
+19.20%
1M Leistung:
+3.66%
6M Leistung:
-13.76%
1J Leistung:
-36.82%
1-Tages-Spanne:
$0.662
$0.7169
1-Wochen-Bereich:
$0.613
$0.7169
52-Wochen-Spanne:
$0.5062
$1.39
Immunic Inc Stock (IMUX) Company Profile
Firmenname
Immunic Inc
Sektor
Branche
Telefon
(332) 255-9818
Adresse
1200 AVENUE OF THE AMERICAS, NEW YORK
Vergleichen Sie IMUX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
0.6946 | 79.71M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.17 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
811.91 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
815.66 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.96 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-07 | Eingeleitet | Roth Capital | Buy |
| 2025-09-29 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-25 | Eingeleitet | William Blair | Outperform |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-27 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-04-15 | Eingeleitet | Aegis Capital | Buy |
| 2021-03-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-07 | Fortgesetzt | ROTH Capital | Buy |
| 2020-07-20 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-06-05 | Eingeleitet | Wedbush | Outperform |
| 2020-05-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-11 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Immunic Inc Aktie (IMUX) Neueste Nachrichten
Can Immunic Inc. stock beat market expectations this quarterTrade Entry Report & AI Driven Stock Price Forecasts - ulpravda.ru
Can Immunic Inc. stock maintain operating marginsJobs Report & Consistent Profit Trade Alerts - ulpravda.ru
Will Immunic Inc. stock see insider buyingJuly 2025 Volume & High Accuracy Investment Entry Signals - ulpravda.ru
Why Immunic Inc. (10VA) stock appears on watchlists2025 Buyback Activity & Long-Term Growth Portfolio Plans - ulpravda.ru
Will Immunic Inc. stock keep outperforming rivals2025 Growth vs Value & Reliable Entry Point Alerts - ulpravda.ru
Immunic (NASDAQ:IMUX) Given Buy Rating at D. Boral Capital - Defense World
Immunic looks to 2026 data as late-stage MS program advances - Proactive financial news
Immunic CEO on key 2025 highlights and 2026 milestones - Proactive financial news
EQS-News: Immunic AG: Immunic Highlights 2025 Accomplishments and Upcoming Milestones - FinanzNachrichten.de
Immunic Highlights 2025 Accomplishments and Upcoming Milestones - PR Newswire
Immunic Transfers Listing to Nasdaq Capital Market for Compliance - TipRanks
Immunic to transfer listing to Nasdaq Capital Market after bid price non-compliance - Investing.com
Immunic Announced Transfer or Voluntary Withdrawal of Listing - TradingView — Track All Markets
Immunic (NASDAQ:IMUX) Shares Up 9.3% – Should You Buy? - Defense World
Immunic appoints Duane Nash as CEO of new subsidiary Gliomic, updates executive agreements - Investing.com Australia
Immunic appoints Duane Nash as CEO of new subsidiary Gliomic, updates executive agreements By Investing.com - Investing.com South Africa
Immunic, Inc. Announces Executive Role Changes - TradingView — Track All Markets
Immunic (IMUX) Has a New Rating from Chardan Capital - The Globe and Mail
Celiac Disease Market Report 2025-2035: Drivers, Challenges, Opportunities, Industry Trends and Case Studies - GlobeNewswire Inc.
Immunic Earnings Notes - Trefis
Gainers Report: Will Immunic Inc 10VA stock benefit from mergers2025 Fundamental Recap & Reliable Breakout Forecasts - moha.gov.vn
Will Immunic Inc. (10VA) stock benefit from mergersJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - Улправда
Will Immunic Inc. (10VA) stock extend growth storyWeekly Trade Summary & AI Based Buy/Sell Signal Reports - DonanımHaber
Why Immunic Inc. (10VA) stock stays resilientQuarterly Profit Review & Daily Chart Pattern Signals - DonanımHaber
Will Immunic Inc. stock outperform international peersStock Surge & Intraday High Probability Alerts - Улправда
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Immunic (IMUX) - The Globe and Mail
Immunic Inc (IMUX)’s stock performance: a year in review - uspostnews.com
Immunic launches public offering of warrants to fund clinical trials; shares down - MSN
683 Capital Management LLC Reduces Stake in Immunic, Inc. $IMUX - Defense World
Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of “Buy” by Analysts - Defense World
Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of "Buy" by Analysts - MarketBeat
JANUS HENDERSON GROUP PLC Acquires Significant Stake in Immunic Inc - GuruFocus
How does Immunic Inc (IMUX) change from a tortoise to a hare? - setenews.com
Immunic’s long-term treatment hope for multiple sclerosis – ICYMI - Proactive financial news
Operating income of Immunic, Inc. – HAM:10VA - TradingView
Will Immunic Inc. stock deliver better than expected guidanceRisk Management & Real-Time Buy Signal Alerts - Newser
How risky is Immunic Inc. stock nowJuly 2025 Reactions & Short-Term High Return Strategies - Newser
Will Immunic Inc. (10VA) stock return to pre crash levels2025 Fundamental Recap & Consistent Profit Alerts - Newser
How supply chain issues affect Immunic Inc. stockMarket Activity Recap & Weekly Sector Rotation Insights - Newser
Why Immunic Inc. (10VA) stock is a strong analyst pickPortfolio Gains Summary & Technical Pattern Alert System - Newser
Can Immunic Inc. (10VA) stock withstand sector downturnsTrade Exit Summary & Real-Time Buy Zone Alerts - Newser
Is Immunic Inc. stock near bottom after declineOil Prices & Daily Momentum Trading Reports - Newser
How Immunic Inc. stock performs in stagflation2025 Investor Takeaways & Target Return Focused Picks - Newser
Immunic marks International Day of Persons with Disabilities with hope for MS sufferers - Proactive financial news
What consensus target says about Immunic Inc. (10VA) stockWeekly Risk Summary & Safe Capital Growth Stock Tips - Newser
Why Immunic Inc. stock is considered a top pickPortfolio Value Summary & AI Based Buy/Sell Signal Reports - Newser
Will Immunic Inc. (10VA) stock outperform Dow JonesTrade Analysis Summary & Technical Confirmation Trade Alerts - Newser
IMUX stock touches 52-week low at $0.92 amid market challenges - MSN
Will Immunic Inc. (10VA) stock outperform global peers2025 Market Trends & Weekly Watchlist for Hot Stocks - Newser
Immunic (IMUX) Stock Analysis Report | Financials & Insights - Benzinga
B. Riley Has Bullish Estimate for Immunic FY2025 Earnings - MarketBeat
Finanzdaten der Immunic Inc-Aktie (IMUX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunic Inc-Aktie (IMUX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Tardio Jason | President and COO |
Jun 05 '25 |
Buy |
0.79 |
12,512 |
9,884 |
12,512 |
| Vitt Daniel | CEO and Director |
Jun 04 '25 |
Buy |
0.77 |
15,000 |
11,550 |
29,000 |
| Neermann Joerg | Director |
Jun 04 '25 |
Buy |
0.77 |
70,000 |
53,900 |
170,000 |
| Neermann Joerg | Director |
Jun 05 '25 |
Buy |
0.76 |
30,000 |
22,800 |
200,000 |
| Whaley Glenn | Chief Financial Officer |
Jun 03 '25 |
Buy |
0.71 |
45,000 |
32,076 |
95,510 |
| Rudick Richard Alan | Director |
Jun 03 '25 |
Buy |
0.70 |
143,075 |
100,024 |
230,375 |
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):